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Edited by Masayuki MiyasakaAbstract Golgi a-mannosidase II is essential for the eﬃcient
formation of complex-type glycosylation. Here, we demonstrate
that the disruption of Golgi a-mannosidase II activity by swains-
onine in human embryonic kidney cells is capable of inducing a
novel class of hybrid-type glycosylation containing a partially
processed mannose moiety. The discovery of ‘Man6-based’
hybrid-type glycans reveals a broader in vivo speciﬁcity of N-
acetylglucosaminyltransferase I, further deﬁnes the arm-speciﬁc
tolerance of core a1-6 fucosyltransferase to terminal a1-2 man-
nose residues, and suggests that disruption of Golgi a-mannosi-
dase II activity is capable of inducing potentially ‘non-self’
structures.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The complexity of glycosylation is essential for the growth
and development of higher eukaryotic organisms. Numerous
glycosidases and glycosyltransferases orchestrate the conver-
sion of the glucosylated oligomannose-type glycans of nascent
glycoproteins to the hybrid- and complex-type glycosylation
characteristic of mature mammalian glycoproteins [1]. With
the exception of glycans that are protected from glycosidaseAbbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity;
CHO, Chinese hamster ovary; CID, collision-induced dissociation;
dHex, deoxyhexose; ER, endoplasmic reticulum; ESI, electrospray
ionization; Fuc, fucose; Glc, glucose; GlcNAc, N-acetylglucosamine;
GnT, N-acetylglucosaminyltransferase; HEK, human embryonic kid-
ney; Hex, hexose; HexNAc, N-acetylhexosamine; Man, mannose; MIg,
MAM and Ig domains of RPTPl; MS, mass spectrometry; NMR,
nuclear magnetic resonance; PAGE, polyacrylamide gel electrophore-
sis; PBS, phosphate-buﬀered saline; PCR, polymerase chain reaction;
PNGase F, peptide N-glycosidase F; Q, quadrupole; RPTPl; receptor
protein tyrosine phosphatase-l; s, soluble; SDS, sodium dodecyl
sulfate; Tof, time-of-ﬂight
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doi:10.1016/j.febslet.2007.04.020processing by the protein moiety [2], following endoplasmic
reticulum (ER) a-glucosidase I and II, many glycans are
subjected to ER a-mannosidase I cleavage resulting in
D1,D3-Man8GlcNAc2 isomer [3] (compound 6, Fig. 1). Golgi
a-mannosidase IA, IB, IC, complements this activity by hydro-
lyzing the remaining D1 and D3-arm a1-2 mannose residues to
yield Man5GlcNAc2 [4] (compound 5, Fig. 1). Two ancient
enzymatic steps then mediate the main gateway from this
oligomannose-type glycan to the hybrid- and complex-type
glycans capable of signiﬁcant heterogeneity.
Classical hybrid-type glycosylation is formed by the transfer
of b1-2-linked GlcNAc to the 3-arm mannose of the trimanno-
syl core by UDP-N-acetyl-D-glucosamine:a-3-D-mannoside
b1,2-N-acetylglucosaminyltransferase I (GnT I) [5]. The action
of GnT I is permissive for further glycosyltransferase reactions
that lead to increased complexity of the hybrid-type structure,
such as GnT III and FUT8, which catalyze bisecting b1-4 Glc-
NAc and core a1-6 fucosylation, respectively. Golgi a-man-
nosidase II hydrolyzes the unsubstituted a1-3 and a1-6
mannose residues of the 6-anntennae to yield a monoanten-
nary complex-type glycan, which can be further elaborated
by numerous glycosyltransferases in the Golgi apparatus.
Homozygotic mutation of Mgat1, which encodes GnT I, is
embryonically lethal in mice at E9.5 [6,7] whereas disruption
of GnT I activity is tolerated in cell lines [8,9]. The importance
of hybrid and complex-type glycosylation in development is
further supported by the impaired locomotory activity and
brain development in Drosophila melanogaster [10]. The gly-
cans of GnT I-deﬁcient cell lines, such as Chinese hamster
ovary (CHO) Lec3.2.8.1 and ricin-resistant human embryonic
kidney (HEK) 293S cells, are dominated by Man5GlcNAc2
[8,9,11,12]. Only a trace amount of a1-6 fucosylated oligoman-
nose glycans reveal a GnT I-independent glycosyltransferase
activity in mammals [13,14].
In contrast, genetic disruption of Golgi a-mannosidase II,
which leads to the formation of hybrid-type glycans, is found
clinically in humans as congenital dyserythropoietic anemia
type II [15,16]. Mice homozygous for deletions of the murine
Golgi a-mannosidase II gene display similar diserythropoiesis
and develop systemic autoimmune disease similar to human
systemic lupus erythematosus [17]. Chui and others hypothe-
sized that resulting hybrid-type glycans, usually absent or pres-
ent at very low levels on the cell surface, contribute to the
increased autoantibody reactivity [17]. Here, using negativeation of European Biochemical Societies.
Fig. 1. Structures of the glycans whose fragmentation is discussed in
this paper. Key to symbols used to represent monosaccharide
constituents in this and subsequent ﬁgures: (e) Gal, (n) GlcNAc,
(s) Man, ( ) Fuc. The linkage position is shown by the angle of the
lines linking the sugar residues (vertical line = 2-link, forward
slash = 3-link, horizontal line = 4-link, back slash = 6-link). Anome-
ricity is indicated by full lines for b-bonds and broken lines for a-
bonds. Terminal a1-2 mannose residues of Man9GlcNAc2 are termed
the D1, D2 and D3 residues (illustrated on the monoglucosylated
Man9GlcNAc2, compound 7) [31–33]. This labelling is distinct from
the ion nomenclature of Domon and Costello [28].
1964 M. Crispin et al. / FEBS Letters 581 (2007) 1963–1968ion nano-electrospray ionization mass spectrometry, we
demonstrate the biosynthesis in human embryonic kidney cells
of hitherto undescribed Man6-based hybrid-type glycans. The
production of these unusual structures following disruption
of Golgi a-mannosidase II activity are consistent with the
hypothesis that ‘non-self’ structures are formed [17].
In addition, these observations demonstrate that complete
hydrolysis of terminal a1-2 linked mannose residues is not
essential for the formation of hybrid-type glycans. Further-
more, identiﬁcation of a core a1-6 fucosylated derivative of
the Man6-hybrid, reveals that core fucosylation is dependent
on the hydrolysis of the D3 mannose, which may prove a pow-
erful tool in the enhancement of antibody-dependent cell-med-
iated cytotoxicity (ADCC) [18,19].2. Materials and methods
2.1. Materials
Authentic samples of Man5GlcNAc2 (compound 5; Fig. 1) and
D1,D3-Man8GlcNAc2 (compound 6) were obtained from Oxford Gly-
coSciences Ltd. (Abingdon, UK). Glc1Man9GlcNAc2 (compound 7)
was a gift from Dr. M. Mackeen.
2.2. Cloning, expression, and puriﬁcation of RPTPl
A cDNA fragment encoding the two soluble (s) N-terminal domains
(MAM and Ig, termed sMIg [20]) of human receptor protein tyrosine
phosphatase l, (RPTPl), extracellular region (residues 1–279), was
ampliﬁed by polymerase chain reaction (PCR) using the phFL vector
as template [21], a gift from M. Gebbink (University of Utrecht, The
Netherlands), and subcloned into the pHL expression vector [20] in
frame with a C-terminal LysHis6 tag.
HEK 293T (ATCC number CRL-1573), 90% conﬂuent, were tran-
siently transfected with polyethyleneimine [22,23]. The cells were cul-
tured in Dulbecco’s Modiﬁed Eagle’s Medium (Sigma, Poole,
Dorset, UK) supplemented with 10% fetal bovine serum (Sigma,
Poole, Dorset, UK), L-glutamine and non-essential amino acids (Invit-
rogen, Paisley, UK). The serum concentration was lowered to 2%
immediately after transfection. Swainsonine (Toronto Research Chem-
icals, North York, Ontario, Canada) was used at a ﬁnal concentration
of 5 lM and added to the HEK 293T culture medium immediatelyafter transfection. Conditioned media, containing the secreted fusion
protein, were collected 4 days post-transfection, centrifuged, sterile ﬁl-
tered and then diluted with two volumes of phosphate-buﬀered saline
(PBS). The pH was adjusted to 8.0 with 10 mM Tris–HCl. The His-
tagged protein was bound to Ni2+-charged chelating Sepharose (Amer-
sham Biosciences, Uppsala, Sweden) in batch mode at 16 C for 4 h,
then the beads were packed in BioRad Econo columns, washed with
20 bed volumes of PBS supplemented with 0.1% Tween-20 followed
by 20 bed volumes PBS. Bound proteins were eluted in 100 mM
Tris–HCl, pH 8, 500 mM NaCl, 500 mM imidazole, concentrated
and subjected to gel-ﬁltration using a Superdex 200 HR column
(Amersham Biosciences, Uppsala, Sweden) equilibrated in 100 mM
Tris–HCl, pH8, 500 mM NaCl. Fractions containing the target protein
at >95% purity, as judged by SDS–PAGE, were pooled, quantiﬁed and
stored at 4 C.2.3. Enzymatic release of N-linked glycans
Oligosaccharides were released from MIg with protein N-glycanse
(PNGase) F (Prozyme, San Leandro, CA, USA) from Coomassie
blue-stained SDS–PAGE gels containing the target glycoprotein [24].
Bands containing approximately 10 lg of target glycoprotein were ex-
cised from reducing SDS–PAGE gels and washed with 20 mM NaH-
CO3 pH 7.0. The washed gel bands were dried in a vacuum
centrifuge before rehydration with 30 ll of 30 mM NaHCO3 pH 7.0,
containing 100 Units/ml of peptide N-glycosidase F (PNGase F). After
incubation for 12 h at 37 C, the enzymatically released N-linked gly-
cans were eluted with water. Salts were removed with by incubation
at RT (5 min) with 200 ll of an acid-activated AG-50W (200–400
mesh) slurry (BioRad, Hercules, CA, USA) which was removed by ﬁl-
tration with a 0.45 ll pore-size ﬁlter (Millex-LH, hydrophobic polytet-
raﬂuoroethylene).2.4. Electrospray mass spectrometry
Electrospray mass spectrometry was performed with a Waters-
Micromass quadrupole-time-of-ﬂight (Q-Tof) Ultima Global instru-
ment in negative ion mode. Samples in 1:1 (v:v) methanol:water were
infused through Protana nanospray capillaries (Protana, Odense, Den-
mark). The ion source conditions were as follows: temperature, 120 C;
nitrogen ﬂow 50 1/h; infusion needle potential, 1.2 kV; cone voltage
100 V; RF-1 voltage 150 V. Spectra (2 s scans) were acquired with a
digitization rate of 4 GHz and accumulated until a satisfactory sig-
nal:noise ratio had been obtained. For MS/MS data acquisition, the
parent ion was selected at low resolution (about 5 m/z mass window)
to allow transmission of isotope peaks and fragmented with argon at
a pressure (recorded on the instrument’s pressure gauge) of 0.5 mBar.
The voltage on the collision cell was adjusted with mass and charge to
give an even distribution of fragment ions across the mass scale. Typ-
ical values were 80–120 V. Other voltages were as recommended by the
manufacturer. Instrument control, data acquisition and processing
were performed with MassLynx software Version 4.0 (Water-Micro-
mass, Manchester, UK).3. Results
3.1. Identiﬁcation of Man6-based hybrid-type glycans
RPTPl is involved in neural and vascular development and
it has been extensively studied for its cell adhesive properties
[20,25,26]. We sought to investigate the post-translational pro-
cessing of the RPTPl extracellular domains. Recombinant
sMIg, containing domains critical for adhesion, was expressed
in HEK 293T cells in the presence of 20 lM of the potent
Golgi a-mannosidase II inhibitor, swainsonine. Glycans were
released by in-gel PNGase F digestion and analyzed by electro-
spray mass spectrometry. Fig. 1 depicts the structure of
the N-linked glycans discussed herein (compounds 1–7).
Collision-induced decomposition (CID) of the molecular ions
produced non-standard spectra which we here assign to unu-
sual Man6-based hybrid structures (compounds 3 and 4).
The relative abundance of the Man6-based glycans were
Fig. 2. Negative ion ESI-CID spectrum of classical hybrid-type N-linked glycans from sMIg expressed in HEK 293T cells in the presence of
swainsonine. Symbols as Fig. 1. Ion nomenclature follows the method of Domon and Costello [28].
M. Crispin et al. / FEBS Letters 581 (2007) 1963–1968 1965between 20% and 30% of the corresponding Man5-based hy-
brid-type glycan (data not shown). Fig. 2 shows the negativeFig. 3. Negative ion ESI-CID spectrum of non-canonical hybrid-type N-link
swainsonine. Symbols as Fig. 1. Ion nomenclature follows the method of Dion nano-electrospray MS/MS spectra of classical hybrid N-
linked oligosaccharides (phosphate adducts) containing ﬁveed glycans from sMIg expressed in HEK 293T cells in the presence of
omon and Costello [28].
1966 M. Crispin et al. / FEBS Letters 581 (2007) 1963–1968mannose residues with and without a fucose residues (Fig. 2a
and b, respectively). Similarly, Fig. 3 depicts the MS/MS spec-
tra of the corresponding hybrid-type glycans containing six
mannose residues (Fig. 3a and b). The fucose residues in com-
pounds 2 and 4 were located at the 6-position of the reducing-
terminal GlcNAc residue as determined by the mass of the
2,4AR, BR and
2,4AR1 ions [27], following the nomenclature
of Domon and Costello [28], which appeared at the same mass
in the spectra of fucosylated and non-fucosylated compounds
following loss of the fucose. The ion at m/z 424 is a cross-ring
fragment containing hexose–HexNAc and two extra carbon
atoms with their substituents from the attached mannose
(1,3A3a). C2 ion at m/z 503 (Man3) and the C3a ion at m/z
665 (Man4) in the spectra of the compounds 1 and 2 (Fig. 2a
and b) and compounds 3 and 4 (Fig. 3a and b), respectively,
conﬁrm the hybrid nature of these compounds and the D,
[D-18] and O,3AR2 ions (m/z 647, 629 and 575, compounds
1 and 2; m/z 809, 791 and 737, compounds 3 and 4) conﬁrm
that the mannose residues are in the 6-antenna [23].Fig. 4. Negative ion ESI-CID spectra of oligomannose-type N-link
(c) Glc1Man9GlcNAc2. Symbols as Fig. 1. Ion nomenclature follows the me3.2. Man6-based hybrid-type glycans contain arm-speciﬁc
mannose
The sixth mannose in compounds 3 and 4 is located on the 3-
branch of the 6-antenna based on the following evidence. Be-
cause the substitution pattern around the branching mannose
of the 6-antenna is the same as that of the core mannose, an
ion corresponding to the D ion (containing the core mannose
and 6-antenna, Fig. 1) would be expected. This ion, termed the
D 0 ion can be seen at m/z 323 (containing two mannose resi-
dues) in the spectra of compound 1 (Fig. 2a) and Man5Glc-
NAc2 (compound 5; Fig. 4a). The extra mannose on the 6-
branch of the 6-antenna (termed the D3 mannose) in the spec-
trum of the reference sample of D1,D3-Man8GlcNAc2 (com-
pound 6; Fig. 4b) shifts this ion to m/z 485. If this mannose
were substituted on the 3-branch, no shift would be observed,
consistent with the spectrum of Man9GlcNAc2 (data not
shown; [29]) and Glc1Man9GlcNAc2 (compound 7; Fig. 4c)
where the additional mannose does not cause a peak shift.
Although it could be argued that an ion of composition ofed glycans: (a) Man5GlcNAc2; (b) D1,D3-Man8GlcNAc2; and
thod of Domon and Costello [28].
Golgi α-mannosidase
IA, IB and IC
ER α-mannosidase I
M. Crispin et al. / FEBS Letters 581 (2007) 1963–1968 1967Man3 (m/z 485) could originate from the 3-antenna in the spec-
trum of D1,D3-Man8GlcNAc2 (compound 6; Fig. 4b) this can
be ruled out because the presence of an additional glucose res-
idue in this antenna in Glc1Man9GlcNAc2 (compound 7) does
not produce a shift to m/z 647 (Fig. 4c). In the spectra of the
hybrid glycans shown in Fig. 3a and b, there is no signiﬁcant
D 0 ion at m/z 485, but there is a signiﬁcant ion at m/z 323
(as in the spectra of the Man5-containing compounds, 1, 2,
and 5). Thus the sixth mannose must be located on the 3-
branch of the 6-antenna (D2).GlcNAc Transferase I
Further processing
Man6-based hybrids Classical hybrids
Fig. 5. Proposed pathway for the formation of classic and non-
canonical hybrid-type glycans. Symbols as Fig. 1.4. Discussion
Classical hybrid-type glycans are formed by the action of
GnT I on Man5GlcNAc2 glycans. The discovery of speciﬁc
Man6-based hybrids, demonstrates that lack of processing of
the D2 arm is tolerated for GnT I catalysis. Importantly, this
activity is supported by in vitro studies of recombinant GnT I
by Fujiyama and others [30]. Additional enzymological details
of the N-linked glycosylation pathway are revealed by the dis-
covery of the biosynthesis of fucosylated Man6-based hybrid-
type structures. This further deﬁnes the structural basis of
the inhibitory eﬀect of 6-antennae a1-2 linked mannose resi-
dues on core a1-6 fucosylation [14]. Although Man9GlcNAc2
is not core fucosylated, core a1-6 fucosyltransferase can
fucosylate Glc1Man7GlcNAc2 and Man5GlcNAc2 [14]. Thus,
in contrast to the D1-arm, either or both of the D2 or D3
a1-2 mannose residues suppress core fucosylation [14]. The
biosynthesis of core fucosylated D2-Man6-based hybrids sug-
gests that the hydrolysis of only the D3 mannose is necessary
for core a1-6 fucosylation in mammals. The nuclear magnetic
resonance (NMR) [31,32] and crystal structure [33] of
Man9GlcNAc2 demonstrated that the D3 mannose is located
on the same side of the molecule as the C6 position of the
reducing terminal GlcNAc and may prevent substrate recogni-
tion by a1-6 fucosyltransferase.
The absence of core a1-6 fucosylation can signiﬁcantly en-
hance ADCC eﬀector function of antibodies [19]. Conse-
quently, cell lines are being developed for the expression of
antibodies that are devoid of fucosylation [18]. The potent
inhibition of core fucosylation in mammalian cell lines by
D3-mannose suggests a further route to the modulation of
antibody eﬀector functions. For example, the expression of
antibodies in the presence of the a-mannosidase inhibitor, kif-
unensine [34], would result in oligomannose-type glycans with
intact D3-mannose completely devoid of core fucosylation
[14]. Interestingly, the oligomannose-type glycans of the Fc
would also inﬂuence other aspects of the antibody function
such as increasing the clearance rate from serum [35].
Although the exact biosynthetic origin of Man6-based hy-
brids is unknown, the highest activity for the hydrolysis of
the D2 mannose amongst the class I a-mannosidases is exhib-
ited by ER a-mannosidase I, which results in D1,D3-Man8Glc-
NAc2 isomers entering the Golgi apparatus [3]. In contrast, the
remaining class I a-mannosidases, Golgi a-mannosidases IA,
IB and IC, exhibit the lowest activity to the D2 mannose which
is the last residue to be cleaved when Man9GlcNAc2 is digested
in vitro [36,37]. Indeed, comparison of all the class I processing
a-mannosidases reveals that in the absence of ER a-mannosi-
dase I cleavage, D2-Man6GlcNAc2 is the most abundant
Man6GlcNAc2 isomer [37]. This suggests that the Man6-basedhybrids are formed by incomplete digestion by, predomi-
nantly, ER a-mannosidase I (Fig. 5).
The induction of novel structures, such as biantennary Lewis
X hybrid-type glycans, induced by the putative anti-cancer
agent, swainsonine, led Chui and others to propose that they
may contribute to the lowering of the threshold for lympho-
cyte activation and autoimmunity caused by the disruption
of Golgi a-mannosidase II activity [17]. Here we expand the
repertoire of known swainsonine-induced ‘non-self’ structures
to include Man6-based hybrids.
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